XNASZIVO
Market cap68mUSD
Jan 07, Last price
19.36USD
1D
-2.71%
1Q
-1.73%
Jan 2017
-57.54%
Name
Zivo Bioscience Inc
Chart & Performance
P/E
—
P/S
2,483.08
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
38.94%
Rev. gr., 5y
%
Revenues
28k
Net income
-8m
L-11.07%
CFO
-6m
L-18.34%
Earnings
Mar 13, 2025
Profile
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is based in Bloomfield Hills, Michigan.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 28 | ||||||||
Cost of revenue | 7,291 | 8,732 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (7,263) | (8,732) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (4) | ||||||||
Tax Rate | |||||||||
NOPAT | (7,263) | (8,732) | |||||||
Net income | (7,777) -11.07% | (8,745) -6.93% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 640 | ||||||||
BB yield | -31.56% | ||||||||
| Debt | |||||||||
Debt current | 346 | 339 | |||||||
Long-term debt | 106 | 311 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | 178 | (1,149) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (5,800) | (7,103) | |||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | 4,275 | (629) | |||||||
FCF | (5,182) | 46,491 | |||||||
| Balance | |||||||||
Cash | 274 | 1,799 | |||||||
Long term investments | |||||||||
Excess cash | 273 | 1,799 | |||||||
Stockholders' equity | (123,579) | (115,795) | |||||||
Invested Capital | 121,720 | 116,230 | |||||||
ROIC | |||||||||
ROCE | 390.59% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 1,690 | 1,570 | |||||||
Price | 1.20 -92.00% | 15.00 -12.89% | |||||||
Market cap | 2,028 -91.39% | 23,549 7.55% | |||||||
EV | 2,206 | 22,400 | |||||||
EBITDA | (6,823) | (9,506) | |||||||
EV/EBITDA | |||||||||
Interest | 514 | 13 | |||||||
Interest/NOPBT | |||||||||